Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.60    -0.05 (-1.08%)
Bid:
4.55
Ask:
4.615
Spread: 0.065 (1.429%)
Market Cap: £220.78m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

1st Glaucoma Trial Completion

10 Jan 2006 09:18

Seeing Machines Limited10 January 2006 10 January 2006 SEEING MACHINES LIMITED ("Seeing Machines" or "the Company") NON -CONTACT OBJECTIVE GLAUCOMA DEVICE SUCCESSFULLY COMPLETES FIRST MAJOR CLINICAL TRIAL Seeing Machines Limited (AIM : SEE), a leading developer of advanced computerbased imaging software systems, announces the completion of the first majorclinical trial of its new groundbreaking technology for objective detection andmanagement of glaucoma, the group of eye diseases that affect peripheral vision,often leading to permanent loss of vision. Seeing Machines is developing a new medical device that assists clinicians todiagnose and manage disorders of the human visual system, particularly glaucoma. This recent trial has demonstrated with meaningful clinical utility, that thetechnology, as it stands today: • successfully detects the loss of visual field associated withglaucoma, and • successfully differentiates between those patients with visual fieldloss and those without, thus providing the basis for a reliable and accuratediagnostic instrument. Furthermore the trial has demonstrated significant opportunities for greatlyimproving the performance of the technology from the base-line used in thistrial. Commenting on the trial, Nick Cerneaz, Chief Executive of Seeing Machines said: "The technical progress demonstrated in this trial has assisted Seeing Machinesin reaching a key milestone of our entire medical device development program.Our scientific teams, led by Drs. Ted Maddess and Andrew James from theAustralian National University, have done a tremendous job so far and we are nowwell advanced in the development work arising from this trial. The preparationsfor the next major clinical trial aimed at testing these developments are wellunderway with an anticipated start date this quarter. We are very excited aboutthese results and keen to build further on them as we pursue our goal ofdelivering the world's first non-contact objective test for glaucoma." Enquiries:Seeing Machines Limited Insinger de Beaufort Parkgreen CommunicationsNick Cerneaz, CEO Simon Fox Justine Howarth / Victoria Thomas+61 (0) 2 6125 6501 +44 (0) 20 7190 7018 +44 (0) 20 7493 3713www.seeingmachines.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Apr 20204:36 pmRNSPrice Monitoring Extension
1st Apr 20207:00 amRNSAutomotive License Deal
20th Mar 202011:06 amRNSSecond Price Monitoring Extn
20th Mar 202011:01 amRNSPrice Monitoring Extension
17th Mar 20204:41 pmRNSSecond Price Monitoring Extn
17th Mar 20204:37 pmRNSPrice Monitoring Extension
17th Mar 202011:05 amRNSSecond Price Monitoring Extn
17th Mar 202011:00 amRNSPrice Monitoring Extension
17th Mar 20207:00 amRNSCOVID-19 Update
16th Mar 20204:41 pmRNSSecond Price Monitoring Extn
16th Mar 20204:36 pmRNSPrice Monitoring Extension
10th Mar 20207:00 amRNSHalf year results to 31 December 2019
4th Mar 20207:00 amRNSAppointment of Joint Broker
30th Jan 20207:00 amRNSHalf year trading update
27th Jan 202010:52 amRNSHolding(s) in Company
13th Jan 20207:44 amRNSFOVIO Chip to display at Automotive World Tokyo
9th Jan 20207:00 amRNSSEE and Qualcomm Combine to Deliver DMS Technology
6th Jan 20207:00 amRNSSEE to showcase DMS technology at CES 2020
6th Jan 20207:00 amRNSFOVIO Chip optimized for NCAP readiness
16th Dec 201910:38 amRNSHolding(s) in Company
28th Nov 20198:00 amRNSResult of AGM
22nd Nov 20199:44 amRNSHolding(s) in Company
20th Nov 20199:31 amRNSUS NTSB Recommends Driver Monitoring
13th Nov 20197:00 amRNSBoard Changes - Seeing Machines Appoints New NEDs
11th Nov 20199:58 amRNSEuropean Council Adopts Enhanced Safety Regulation
8th Nov 20191:28 pmRNSHolding(s) in Company
7th Nov 20199:50 amRNSCapital Markets Day Presentation
6th Nov 20197:00 amRNSBusiness Update
30th Oct 20197:00 amRNSNotice of AGM
25th Oct 20197:00 amRNSFleet deal with North America's Safest Fleet
22nd Oct 201911:34 amRNSShare Transfer and Issue of Performance Rights
11th Oct 201912:00 pmRNSHolding(s) in Company
2nd Oct 20197:33 amRNSCollaboration with Alaska Airlines
1st Oct 201910:14 amRNSDirector/PDMR Shareholding
30th Sep 20197:00 amRNSCEO Long Term Incentive Plan
27th Sep 201911:50 amRNSHolding(s) in Company
23rd Sep 20197:00 amRNSYear End Results
19th Sep 20199:18 amRNSWebcast Presentation - Year End Results
18th Sep 20197:00 amRNSHolding(s) in Company
2nd Sep 20197:00 amRNSExpanded program award for existing OEM customer
30th Aug 20199:02 amRNSNotice of Results & Capital Markets Day
1st Aug 20197:00 amRNSPost Close Trading Update
30th Jul 20197:00 amRNSGuardian Award with National Express
23rd Jul 20197:00 amRNSAutomotive Design Win Targeting Euro NCAP
22nd Jul 20197:00 amRNSBoard Changes
12th Jul 20192:01 pmRNSStatement re: Press Speculation
4th Jul 20197:00 amRNSLeadership Changes
13th Jun 20197:00 amRNSFleet Momentum in New Zealand
10th Jun 20197:00 amRNSSelf-driving car company signs Guardian BdMS deal
7th Jun 201911:49 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.